Sartorius Stedim Biotech SA: Half-year liquidity contract statement for Sartorius Stedim Biotech
Sartorius Stedim Biotech SA
Sartorius Stedim Biotech SA: Half-year liquidity contract statement for Sartorius Stedim Biotech
05-Jan-2022 / 14:31 CET/CEST
Dissemination of a French Regulatory News, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.
Aubagne, January 5, 2022
Half-year liquidity contract statement for Sartorius Stedim Biotech
Under the liquidity contract entered into between Sartorius Stedim Biotech and Kepler Cheuvreux, the following resources appeared on the liquidity account on December 31st 2021:
3,361 shares € 9,978,179.44 Number of executions on buy side on semester: 2,810 Number of executions on sell side on semester: 2,600 Traded volume on buy side on semester: 95,701 shares for € 44,247,756.63 Traded volume on sell side on semester: 94,714 shares for € 45,073,166.52
As a reminder :
the following resources appeared on the last half year statement on 30 June 2021 on the liquidity account:
2,374 shares € 9,177,482.91
Number of executions on buy side on semester: 659 Number of executions on sell side on semester: 538 Traded volume on buy side on semester: 24,109 shares for € 8,777,527.71 Traded volume on sell side on semester: 21,735 shares for € 7,961,330.63
the following resources appeared on the liquidity account when the activity started:
0 shares € 10,000,000.00
The implementation of this report is carried out in accordance with AMF Decision N°2021-01 of June
22nd 2021 renewing the implementation of liquidity contracts for shares as an accepted market practice.
A profile of Sartorius Stedim Biotech
Sartorius Stedim Biotech is a leading international partner of the biopharmaceutical industry. As a total solutions provider, the company helps its customers to manufacture biotech medications safely, rapidly and economically. Headquartered in Aubagne, France, Sartorius Stedim Biotech is quoted on the Eurolist of Euronext Paris. With its own manufacturing and R&D sites in Europe, North America and Asia and an international network of sales companies, Sartorius Stedim Biotech has a global reach. The Group has been annually growing by double digits on average and has been regularly expanding its portfolio by acquisitions of complementary technologies. In 2020, the company employed more than 7,500 people, and earned sales revenue of 1,910 million euros.
Contact
Petra Kirchhoff
Head of Corporate Communications & Investor Relations
+49 (0)551.308.1686
Petra.kirchhoff@sartorius.com
Sartorius Stedim Biotech S.A.
Z.I. Les Paluds
Avenue de Jouques, CS 91051
13781 Aubagne Cedex, France
Phone: +33.(0)4.42.84.56.00
Fax: +33.(0)4.42.84.56.19
www.sartorius-stedim.com
APPENDIX H2 2021
Buy side
Sell side
Number of executions
Number of shares
Traded volume in EUR
Number of executions
Number of shares
Traded volume in EUR
TOTAL
2,810
95,701
44,247,756.63
2,600
94,714
45,073,166.52
01/07/2021
52
2,000
790,040.00
11
300
120,741.00
02/07/2021
4
300
118,200.00
20
500
198,220.00
05/07/2021
11
400
157,400.00
6
104
41,275.52
06/07/2021
-
-
-
51
2,096
859,234.24
07/07/2021
-
-
-
26
1,100
467,203.00
08/07/2021
-
-
-
9
400
175,200.00
09/07/2021
41
1,300
563,784.00
-
-
-
12/07/2021
-
-
-
45
1,100
485,100.00
13/07/2021
13
600
262,422.00
7
300
133,860.00
14/07/2021
1
51
22,593.00
4
300
134,700.00
16/07/2021
-
-
-
9
200
91,900.00
19/07/2021
42
1,349
613,646.61
4
100
46,250.00
20/07/2021
35
1,900
857,451.00
-
-
-
21/07/2021
143
5,996
2,620,431.88
32
1,009
458,802.39
22/07/2021
16
500
218,000.00
82
2,091
938,900.82
23/07/2021
1
100
45,600.00
38
1,175
542,732.50
26/07/2021
21
900
413,091.00
20
625
291,443.75
27/07/2021
10
400
181,772.00
20
800
368,400.00
28/07/2021
3
200
92,300.00
34
1,000
468,500.00
29/07/2021
11
400
187,400.00
7
200
94,700.00
30/07/2021
11
400
187,600.00
31
1,400
671,300.00
02/08/2021
10
500
239,500.00
15
400
193,400.00
03/08/2021
2
100
48,300.00
11
500
243,620.00
04/08/2021
6
100
48,300.00
14
500
246,000.00
05/08/2021
-
-
-
22
600
297,300.00
06/08/2021
52
1,600
776,800.00
-
-
-
09/08/2021
-
-
-
18
500
244,000.00
10/08/2021
1
100
49,000.00
30
856
423,035.20
11/08/2021
15
600
291,900.00
-
-
-
12/08/2021
18
701
336,472.99
4
144
69,651.36
13/08/2021
2
199
94,923.00
-
-
-
16/08/2021
14
200
95,100.00
5
300
144,600.00
17/08/2021
-
-
-
40
1,700
835,992.00
18/08/2021
-
-
-
26
1,000
504,500.00
19/08/2021
67
1,900
935,351.00
19
600
296,442.00
20/08/2021
5
100
50,000.00
42
1,500
755,595.00
23/08/2021
-
-
-
5
200
103,300.00
24/08/2021
-
-
-
1
100
52,000.00
25/08/2021
-
-
-
1
100
52,500.00
31/08/2021
-
-
-
4
100
53,060.00
20/09/2021
98
1,200
596,700.00
4
400
208,200.00
21/09/2021
-
-
-
36
800
423,384.00
23/09/2021
-
-
-
4
200
107,600.00
27/09/2021
120
3,500
1,722,770.00
-
-
-
28/09/2021
146
3,614
1,708,265.52
-
-
-
29/09/2021
-
-
-
113
3,200
1,556,512.00
30/09/2021
-
-
-
4
200
98,500.00
01/10/2021
125
5,000
2,309,750.00
9
400
189,200.00
04/10/2021
125
5,491
2,416,534.19
1
100
45,200.00
05/10/2021
7
100
43,540.00
82
3,300
1,479,258.00
06/10/2021
39
1,400
620,704.00
-
-
-
07/10/2021
50
2,200
968,990.00
44
851
380,082.13
08/10/2021
17
700
305,900.00
17
749
331,597.28
11/10/2021
35
1,000
429,500.00
6
300
129,600.00
12/10/2021
10
200
85,800.00
49
2,104
924,729.04
13/10/2021
-
-
-
110
3,596
1,628,700.32
Buy side
Sell side
Number of executions
Number of shares
Traded volume in EUR
Number of executions
Number of shares
Traded volume in EUR
14/10/2021
1
100
45,660.00
53
2,000
933,460.00
15/10/2021
10
400
186,200.00
37
600
283,002.00
18/10/2021
24
700
324,618.00
8
400
187,860.00
19/10/2021
26
1,200
560,400.00
35
1,100
523,699.00
20/10/2021
99
3,200
1,467,872.00
27
3,200
1,498,272.00
21/10/2021
1
100
46,900.00
36
2,000
959,000.00
22/10/2021
8
500
239,500.00
52
600
291,900.00
25/10/2021
-
-
-
26
700
338,338.00
26/10/2021
48
1,900
901,987.00
34
1,100
528,902.00
27/10/2021
60
2,516
1,189,439.00
10
600
288,900.00
28/10/2021
12
384
180,311.04
19
800
380,400.00
29/10/2021
2
100
47,100.00
-
-
-
01/11/2021
-
-
-
23
1,100
533,500.00
02/11/2021
5
200
96,300.00
14
700
344,400.00
03/11/2021
-
-
-
6
200
99,300.00
04/11/2021
2
100
49,300.00
15
400
199,800.00
05/11/2021
218
5,200
2,432,092.00
-
-
-
08/11/2021
-
-
-
38
2,800
1,318,212.00
09/11/2021
18
400
186,940.00
21
600
283,500.00
10/11/2021
69
4,000
1,830,200.00
2
11
5,071.00
11/11/2021
12
300
136,101.00
19
789
364,731.03
12/11/2021
-
-
-
20
1,000
470,500.00
15/11/2021
8
200
94,700.00
22
800
382,000.00
16/11/2021
18
800
378,200.00
4
100
47,800.00
17/11/2021
8
300
142,200.00
38
1,300
626,197.00
18/11/2021
16
505
243,697.85
15
700
338,898.00
19/11/2021
-
-
-
116
5,200
2,577,380.00
22/11/2021
12
700
345,499.00
12
400
204,600.00
23/11/2021
212
6,295
2,979,990.05
20
500
239,500.00
24/11/2021
29
1,106
518,183.12
20
1,200
567,936.00
25/11/2021
-
-
-
56
1,700
817,666.00
26/11/2021
17
400
191,100.00
128
4,305
2,161,239.15
29/11/2021
37
1,100
561,000.00
47
895
468,980.00
30/11/2021
-
-
-
83
3,045
1,609,982.85
01/12/2021
12
300
149,100.00
-
-
-
02/12/2021
79
2,300
1,124,700.00
-
-
-
03/12/2021
18
800
386,784.00
22
1,000
495,500.00
06/12/2021
125
5,194
2,414,015.38
-
-
-
07/12/2021
-
-
-
103
4,169
1,985,027.66
08/12/2021
2
100
47,700.00
48
1,900
931,304.00
09/12/2021
8
200
95,500.00
-
-
-
10/12/2021
28
1,300
614,796.00
-
-
-
13/12/2021
13
500
233,000.00
-
-
-
14/12/2021
63
1,600
728,800.00
-
-
-
15/12/2021
-
-
-
22
800
373,200.00
16/12/2021
13
500
231,500.00
22
1,000
477,600.00
17/12/2021
19
700
319,900.00
-
-
-
20/12/2021
31
600
272,358.00
19
604
284,085.36
21/12/2021
16
700
319,403.00
32
596
277,044.64
22/12/2021
6
200
91,500.00
17
1,000
465,540.00
23/12/2021
5
100
46,300.00
3
200
94,100.00
24/12/2021
-
-
-
3
100
47,100.00
27/12/2021
-
-
-
22
932
443,790.44
28/12/2021
-
-
-
8
368
177,607.84
29/12/2021
-
-
-
9
200
97,400.00
30/12/2021
-
-
-
19
700
343,819.00
31/12/2021
21
600
291,078.00
3
200
99,100.00
File: Half-year liquidity contract statement for Sartorius Stedim Biotech
Language: English Company: Sartorius Stedim Biotech SA Avenue de Jouques 13781 Aubagne France Phone: +33 44 284 5600 E-mail: info@sartorius-stedim.com Internet: www.sartorius-stedim.com ISIN: FR0013154002 Euronext Ticker: DIM AMF Category: Share buyback / Disposal of own shares / Information relating to the liquidity contract EQS News ID: 1265187 End of Announcement EQS News Service
1265187 05-Jan-2022 CET/CEST